Persistence and adherence with proprotein convertase subtilisin/kexin type 9 inhibitors in clinical practice
D Hines, P Rane, J Patel, D Harrison… - Journal of the American …, 2017 - jacc.org
Background: Elevated low-density lipoprotein cholesterol (LDL-C) is associated with
premature atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin …
premature atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin …
Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates
VW Reynolds, ME Chinn, JA Jolly, TN Kelley… - Journal of Clinical …, 2019 - Elsevier
Background Access to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors that
lower low-density lipoprotein cholesterol in patients at high risk of atherosclerotic …
lower low-density lipoprotein cholesterol in patients at high risk of atherosclerotic …
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience
F Gragnano, F Natale, F Fimiani, A Cesaro… - Journal of …, 2018 - journals.lww.com
Methods Between February 2016 and July 2017, we prospectively evaluated 117 patients at
high cardiovascular risk, admitted to our cardiology department. We examined the …
high cardiovascular risk, admitted to our cardiology department. We examined the …
Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study
T Hollstein, A Vogt, T Grenkowitz, T Stojakovic… - Vascular …, 2019 - Elsevier
Background Proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9-I) reduce low-
density lipoprotein (LDL) cholesterol in human studies. Previous studies suggest that …
density lipoprotein (LDL) cholesterol in human studies. Previous studies suggest that …
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in …
N Katsiki, VG Athyros, DP Mikhailidis… - Metabolism-Clinical …, 2017 - metabolismjournal.com
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have been shown to
decrease low-density lipoprotein cholesterol (LDL-C) levels by about 60% on top of statin …
decrease low-density lipoprotein cholesterol (LDL-C) levels by about 60% on top of statin …
[HTML][HTML] Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center
CL Tsai, YH Chang, CH Su, YJ Wu, HI Yeh… - Journal of the Formosan …, 2022 - Elsevier
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and
evolocumab, are currently approved for clinical use by Taiwan National Health Insurance …
evolocumab, are currently approved for clinical use by Taiwan National Health Insurance …
Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab
NR Desai, RP Giugliano, SM Wasserman… - JAMA …, 2017 - jamanetwork.com
Importance Levels of proprotein convertase subtilisin kexin type 9 (PCSK9) vary markedly
across the population and are influenced by genetic and nongenetic factors. Evolocumab is …
across the population and are influenced by genetic and nongenetic factors. Evolocumab is …
Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
J Choi, AM Khan, M Jarmin, N Goldenberg… - Lipids in health and …, 2017 - Springer
Background Efficacy-safety of proprotein convertase subtilisin-kexin type 9 (PCSK9)
inhibitors, alirocumab (ALI) and evolocumab (EVO), have previously been evaluated …
inhibitors, alirocumab (ALI) and evolocumab (EVO), have previously been evaluated …
Recent updates on the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease
DL Dixon, LG Pamulapati, JD Bucheit… - Current atherosclerosis …, 2019 - Springer
Abstract Purpose of Review Atherosclerotic cardiovascular disease (ASCVD) is caused by
elevated levels of low-density lipoprotein cholesterol (LDL-C). Although statins significantly …
elevated levels of low-density lipoprotein cholesterol (LDL-C). Although statins significantly …
Demographic and clinical characteristics of patients prescribed proprotein convertase subtilisin/kexin type 9 inhibitor therapy and patients whose current lipid-lowering …
SJ Baum, RL Wade, P Xiang, J Arellano… - … and Clinical Risk …, 2019 - Taylor & Francis
Purpose Our objective was to describe the demographic and clinical characteristics of real-
world patients in the US with elevated low-density lipoprotein cholesterol (LDL-C) whose …
world patients in the US with elevated low-density lipoprotein cholesterol (LDL-C) whose …